Skip to main content

Table 2 Baseline patterns of drug usage between users and non-users of aspirin in the complete cohort (n = 6,454).

From: Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients - a longitudinal observational study

 

Overall

(n = 6,454)

Aspirin users

(n = 1,619)

Non-aspirin users

(n = 4,835)

p-value†

Anti-diabetic drugs

    

   Insulin

1,203 (18.6%)

458 (28.3%)

745 (15.4%)

< 0.001

   Any oral agent

4,301 (66.6%)

1,128 (69.7%)

3,173 (65.6%)

0.003

Sulphonylurea

3,461 (53.6%)

928 (57.3%)

2,533 (52.4%)

0.001

Metformin

3,189 (49.4%)

839 (51.8%)

2,350 (48.6%)

0.025

Thiazolidinedione

27 (0.4%)

9 (0.6%)

18 (0.4%)

0.322

Anti-hypertensive drugs

    

   Any anti-hypertensive drugs

3,103 (48.1%)

1,135 (70.1%)

1,968 (40.7%)

< 0.001

   Number of anti-hypertensive drugs*

0.8 ± 1.0

1.3 ± 1.1

0.6 ± 0.9

< 0.001

   Any RAS inhibitor

1,632 (25.3%)

615 (38%)

1,017 (21%)

< 0.001

ACE inhibitor

1,519 (23.5%)

564 (34.8%)

955 (19.8%)

< 0.001

AII antagonist

123 (1.9%)

57 (3.5%)

66 (1.4%)

< 0.001

   Thiazide or related diuretic

162 (2.5%)

61 (3.8%)

101 (2.1%)

< 0.001

   Loop diuretic

217 (3.4%)

129 (8%)

88 (1.8%)

< 0.001

   Beta-blocker

756 (11.7%)

386 (23.8%)

370 (7.7%)

< 0.001

   Alpha-blocker

189 (2.9%)

83 (5.1%)

106 (2.2%)

< 0.001

   Calcium channel blocker

1,838 (28.5%)

697 (43.1%)

1,141 (23.6%)

< 0.001

   Centrally-acting agent

309 (4.8%)

117 (7.2%)

192 (4%)

< 0.001

   Vasodilator

19 (0.3%)

12 (0.7%)

7 (0.1%)

< 0.001

Other cardiovascular drugs

    

   Statin

902 (14%)

434 (26.8%)

468 (9.7%)

< 0.001

   Fibrate

232 (3.6%)

76 (4.7%)

156 (3.2%)

0.006

   Digoxin

65 (1%)

33 (2%)

32 (0.7%)

< 0.001

   Anti-arrhythmic drug

20 (0.3%)

9 (0.6%)

11 (0.2%)

0.040

   Oral anticoagulant

59 (0.9%)

9 (0.6%)

50 (1%)

0.080

   Antiplatelet drug other than aspirin

24 (0.4%)

14 (0.9%)

10 (0.2%)

< 0.001

Other drugs

    

   NSAID

157 (2.4%)

46 (2.8%)

111 (2.3%)

0.218

   Oral corticosteroid

83 (1.3%)

19 (1.2%)

64 (1.3%)

0.643

   Proton pump inhibitor

25 (0.4%)

10 (0.6%)

15 (0.3%)

0.085

   Histamine H2-receptor antagonist

191 (3%)

87 (5.4%)

104 (2.2%)

< 0.001

   Misoprostol

1 (0%)

0 (0%)

1 (0%)

0.563

  1. Data are number of patients (%) or mean ± SD
  2. † By Chi-square test for categorical variables and t-test for continuous variables
  3. RAS = renin-angiotensin system, ACE = angiotensin-converting enzyme, AII = angiotensin II, NSAID = non-steroidal anti-inflammatory drug, RAS inhibitor = either an ACE inhibitor or AII antagonist
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840